▲ Peaking
Business
AstraZeneca hopes to ‘achieve amazing things’ with new Kendall Square R&D center
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Astrazeneca
20 trends tracked about this subject — the full history, oldest to newest below.
◼ Archived
Business
Astra Doesn’t Need a Deal for Growth Beyond 2030, CEO Says
AstraZeneca asserts independence for post-2030 growth while investing over $1 billion in a new robotics-driven R&D hub in Cambridge, Massachusetts.
◼ Archived
Business
AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment
7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
AstraZeneca Breast-Cancer Drug Misses Goal in Late-Stage Trial
AstraZeneca's breast cancer pill Etcamah missed its primary goal in a late-stage trial, adding to oral SERD failures.
◼ Archived
Business
🔮 fades ✓
AZ's R&D chief Barr touts internal 'science success story' after IL-33 antibody's stellar showing in COPD
AstraZeneca reports positive Phase III trial results for tozorakimab, a drug targeting COPD exacerbations.
◼ Archived
Business
🔮 fades ✓
New drug shows promise in reducing COPD symptoms in former and current smokers, clinical trials show
AstraZeneca and Sanofi detail new respiratory clinical data at the #ERS26 conference.
◼ Archived
Business
🔮 fades ✓
AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes
AstraZeneca reports significant Phase III trial wins for Tozorakimab, a COPD drug showing broad benefits for current and former smokers.
◼ Archived
Business
🔮 fades ✗
In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs
A failed clinical trial by AstraZeneca and Ionis for eplontersen raises critical questions about the efficacy of silencer drugs in treating heart disease.
◼ Archived
Business
🔮 fades ✓
AstraZeneca Ends Phase 3 Lung Cancer Drug Trial After Review
AstraZeneca ends a Phase 3 lung cancer drug trial for volrustomig after a formal review determines success is unlikely.
◼ Archived
Business
🔮 fades ✓
‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever
Analysts express perplexity as reports indicate active merger talks between Bristol-Myers Squibb and AstraZeneca.
◼ Archived
Business
🔮 fades ✗
Micron, Bristol Myers, Palantir, Circle Internet, SpaceX, and More Stocks That Explain Today’s Market
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✗
AstraZeneca investors baulk at $400 billion Bristol Myers talks
AstraZeneca investors are resisting proposed acquisition talks with Bristol Myers valued at $400 billion.
◼ Archived
Business
🔮 fades ✗
AstraZeneca Shares Fall on Deal Talks With Bristol-Myers
AstraZeneca shares have declined following reports of potential $400 billion merger talks with Bristol Myers Squibb.
◼ Archived
Business
🔮 holds ✓
AstraZeneca holds talks with Bristol Myers Squibb over $400bn tie-up
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✗
GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyard
GSK is launching a $2.5 billion cost-saving initiative to accelerate its late-stage drug pipeline and relocate its research headquarters.
◼ Archived
Business
🔮 fades ✓
Earnings live: AstraZeneca stock rises to kick off a busy earnings week
AstraZeneca’s earnings beat lifts its stock as oncology sales buoy growth and offset a rare drug miss.
◼ Archived
Business
🔮 fades
AstraZeneca erases billions after sobering reveal
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades
Why AstraZeneca Crashed 6%, Leading Two Rivals, Including Pfizer, To Jump
AstraZeneca shares dropped six percent following a heart drug trial setback that simultaneously boosted rival stocks.
◼ Archived
Business
🔮 fades
AstraZeneca and Ionis Stocks Sink on Trial Miss and Analysts See an Overreaction
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades
AstraZeneca, Ionis report major trial failure with heart disease drug
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.